The System demonstrated accuracy above 98%, sensitivity above 94%, and specificity of 100% for the opiate codeine. These figures represent a notable increase from the Company's previous study, which ...
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("Intelligent Bio Solutions" or the "Company"), a medical technology company delivering intelligent, rapid, ...
Intelligent Bio Solutions expects a sixth U.S. patent for its innovative non-invasive drug testing technology, enhancing market entry plans. Intelligent Bio Solutions Inc. (INBS), a medical technology ...
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points ...
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...
Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Tuesday reported a third quarter 2025 loss of 44 cents per share, down from a loss of $1.43 a year ago. The noninvasive testing solutions provider ...
Intelligent Bio Solutions Inc. (NASDAQ:INBS) reported preliminary fiscal fourth quarter revenue results and selected operational highlights on Thursday. Intelligent Bio Solutions is a medical ...
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing ...
Detailed price information for Intelligent Bio Solutions Inc (INBS-Q) from The Globe and Mail including charting and trades.
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-ov ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results